Discovery and preclinical validation of evolution-designed, AI-discovered, synthetically printed biologic molecules for MDR-TB

针对耐多药结核病的进化设计、人工智能发现、合成印刷的生物分子的发现和临床前验证

• 批准号: 10071576
• 金额: $ 61.85万
• 依托单位: AMPLY DISCOVERY LIMITED
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2023
• 资助国家: 英国
• 起止时间: 2023 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=10071576
• 关键词: Discovery; preclinical; validation; evolution; designed

This project is focused on the discovery of best-in-class antimicrobial peptides (AMPs) and the preclinical validation of these new biologic molecules as an effective treatment alternative for multi-drug resistant tuberculosis (MDR-TB).Tuberculosis is a common bacterial infection, typically affecting the lungs, spread through inhalation of tiny droplets of infected matter. Historically the disease had a high mortality rate, however today the disease is considered imminently curable and preventable if treated with the right course of antibiotics. However, MDR-TB involves strains of the bacteria which are resistant to existing antibiotics and are therefore potentially not treatable.MDR-TB is a major emerging public health problem. In 2021, the WHO estimates that 450,000 people developed TB which was resistant to rifampicin (the first line TB drug), and there were 191,000 related deaths. MDR-TB is significantly more expensive and difficult to treat than standard drug-sensitive TB and its rise threatens the progress made in the twentieth century combating TB. An untreatable, uncontrolled MDR-TB epidemic could have huge health and economic implications.

该项目的重点是发现最好的抗菌肽（AMP），并对这些新的生物分子进行临床前验证，作为耐多药结核病（MDR-TB）的有效治疗替代方案。结核病是一种常见的细菌感染，通常影响肺部，通过吸入感染物质的微小液滴传播。从历史上看，这种疾病的死亡率很高，但今天，如果用正确的抗生素治疗，这种疾病被认为是可以立即治愈和预防的。然而，耐多药结核病涉及对现有抗生素具有耐药性的细菌菌株，因此可能无法治疗。耐多药结核病是一个重大的新出现的公共卫生问题。2021年，世卫组织估计有45万人患上对利福平（一线结核病药物）耐药的结核病，并有191，000人死亡。耐多药结核病比标准的药物敏感性结核病昂贵得多，治疗难度也大得多，耐多药结核病的增加威胁到世纪在防治结核病方面取得的进展。一种无法治疗、不受控制的耐多药结核病流行病可能对健康和经济产生巨大影响。